fda tirzepatide obesity approves weight-loss drug Zepbound to treat sleep apnea FDA approval for Zepbound (tirzepatide)

Semaglutide, also known under the brand names of Ozempic, Wegovy, and Rybelsus, has demonstrated the ability to effectively reduce cardiovascular conditions like heart attacks, strokes, and heart-related conditions, while studies are still ongoing for the cardio effects of Tirzepatide (Mounjaro)

Persistent shedding: Hair loss continuing beyond 6-9 months or worsening over time despite nutritional optimization

Research shows mixed results on semaglutides liver effects

10.1016/j.redox.2013.10.005 139 MorettiN

Some individuals experience nausea during initial semaglutide dosing, which further discourages drinking water and other fluids